The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment

IF 6.9 2区 医学 Q1 HEMATOLOGY
Christina Darwish , Kyle Farina , Douglas Tremblay
{"title":"The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment","authors":"Christina Darwish ,&nbsp;Kyle Farina ,&nbsp;Douglas Tremblay","doi":"10.1016/j.blre.2023.101117","DOIUrl":null,"url":null,"abstract":"<div><p><span><span><span>Core binding factor </span>acute myeloid leukemia<span> (CBF AML), defined by t(8;21) or inv(16), is a subset of favorable risk AML. Despite its association with a high complete </span></span>remission rate<span><span> after induction and relatively good prognosis overall compared with other subtypes of AML, relapse risk after induction chemotherapy remains high. Optimizing </span>treatment<span> planning to promote recurrence free survival and increase the likelihood of survival after relapse is imperative to improving outcomes. Recent areas of research have included evaluation of the role of </span></span></span>gemtuzumab<span> in induction and consolidation, the relative benefit of increased cycles of high dose cytarabine<span><span> in consolidation, the utility of hypomethylating agents<span> and kinase inhibitors, and the most appropriate timing of </span></span>stem cell transplant. Surveillance with measurable residual disease testing is increasingly being utilized for monitoring disease in remission, and ongoing investigation seeks to determine how to use this tool for early identification of patients who would benefit from proceeding to transplant. In this review, we outline the current therapeutic approach from diagnosis to relapse while highlighting the active areas of investigation in each stage of treatment.</span></span></p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X23000784","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Core binding factor acute myeloid leukemia (CBF AML), defined by t(8;21) or inv(16), is a subset of favorable risk AML. Despite its association with a high complete remission rate after induction and relatively good prognosis overall compared with other subtypes of AML, relapse risk after induction chemotherapy remains high. Optimizing treatment planning to promote recurrence free survival and increase the likelihood of survival after relapse is imperative to improving outcomes. Recent areas of research have included evaluation of the role of gemtuzumab in induction and consolidation, the relative benefit of increased cycles of high dose cytarabine in consolidation, the utility of hypomethylating agents and kinase inhibitors, and the most appropriate timing of stem cell transplant. Surveillance with measurable residual disease testing is increasingly being utilized for monitoring disease in remission, and ongoing investigation seeks to determine how to use this tool for early identification of patients who would benefit from proceeding to transplant. In this review, we outline the current therapeutic approach from diagnosis to relapse while highlighting the active areas of investigation in each stage of treatment.

核心结合因子急性髓系白血病的核心概念:当前对预后和治疗的考虑
核心结合因子急性髓系白血病(CBF AML),定义为t(8;21)或inv(16),是有利风险AML的一个子集。尽管与其他AML亚型相比,其诱导后的完全缓解率较高,总体预后相对较好,但诱导化疗后的复发风险仍然很高。优化治疗方案以促进无复发生存和增加复发后生存的可能性是改善预后的必要条件。最近的研究领域包括评估gemtuzumab在诱导和巩固中的作用,增加高剂量阿糖胞苷在巩固中的周期的相对益处,低甲基化剂和激酶抑制剂的效用,以及干细胞移植的最合适时机。可测量的残留疾病检测监测越来越多地用于监测缓解期疾病,正在进行的研究旨在确定如何使用该工具早期识别将从移植中受益的患者。在这篇综述中,我们概述了目前从诊断到复发的治疗方法,同时强调了每个治疗阶段的活跃研究领域。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Blood Reviews
Blood Reviews 医学-血液学
CiteScore
13.80
自引率
1.40%
发文量
78
期刊介绍: Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信